GlassScriptPhysician profile
Fallon R Damico
NPI 1942679741
$2,241.23
in general payments reported to CMS, 2019-2025
30 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $433 · 2023: $341 · 2024: $374 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.19 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.31 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Abbott Laboratories | $180.68 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $165.27 | 2021-2023 | |
| Abbvie INC. | $151.54 | 2021-2022 | |
| Amgen INC. | $116.16 | 2022-2023 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $87.52 | 2021-2023 | Arexvy, Shingrix |
| Nestle Healthcare Nutrition INC. | $63.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $59.65 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $55.50 | 2021 | |
| Lilly USA, LLC | $54.30 | 2021-2024 | Mounjaro |
| Astellas Pharma US INC | $53.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $52.95 | 2021-2023 | Breztri |
| Daiichi Sankyo INC. | $45.82 | 2021 | |
| Merck Sharp & Dohme LLC | $42.64 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38.44 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Vanda Pharmaceuticals INC. | $36.33 | 2021-2022 | |
| Nalu Medical, INC. | $31.76 | 2021 | |
| Sunovion Pharmaceuticals INC. | $31.40 | 2021-2022 | |
| Lucid Diagnostics INC. | $28.08 | 2021 | |
| Edwards Lifesciences Corporation | $26.69 | 2022 | |
| Amarin Pharma, INC. | $26.10 | 2021-2022 | |
| Nevro Corp. | $25.28 | 2024 | Senza |
| Sumitomo Pharma America, INC. | $22.42 | 2023-2024 | Gemtesa |
| Redhill Biopharma INC. | $21.86 | 2021 | |
| Exact Sciences Corporation | $18.42 | 2025 | Cologuard Collection Kit |
| Phadia US INC. | $15.38 | 2022 | |
| Allergan, INC. | $14.25 | 2021 | |
| Eisai INC. | $13.65 | 2021 | |
| Alfasigma USA, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fallon Damico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.